Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.36 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880939 | 0.82 | BPTF (0.58) | BPTFHTR6ADRB1DPP4HTR3A | |
| SCHEMBL12635646 | 0.78 | DNMT3A (0.49) | METKDM4EMEN1HTTKMT2A | |
| SCHEMBL1579592 | 0.77 | PRMT5 (0.45) | BPTFHTR6ADRB1 | |
| SCHEMBL2957583 | 0.76 | HTR7 (0.48) | BPTFHTR6ADRB1HRH4HRH3 | |
| SCHEMBL2955161 | 0.75 | HTR7 (0.47) | BPTFHTR6ADRB1HRH4HRH3 | |
| SCHEMBL1580030 | 0.73 | SLC6A2 (0.52) | BPTFADRB1ADRB2 | |
| SCHEMBL1579254 | 0.72 | BPTF (0.43) | BPTFHTR6MAOBADRB1HTR3A | |
| SCHEMBL1579251 | 0.72 | BPTF (0.43) | BPTFHTR6MAOBADRB1HTR3A | |
| SCHEMBL1579440 | 0.72 | BPTF (0.43) | BPTFHTR6MAOBADRB1HTR3A | |
| SCHEMBL1579929 | 0.72 | ADRB1 (0.43) | BPTFHTR6ADRB1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102159554-B | Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2014-09-24 | — | — | CN | disclosed |
| US-8530474-B2 | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-8530474-B2 | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| US-8530474-B2 | Substituted 6-(1-piperazinyl)-pyridazines as 5-HT6 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-10 | — | — | US | disclosed |
| EP-2310374-B1 | SUBSTITUTED 6- (1-PIPERAZINYL) -PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-31 | — | — | EP | disclosed |
| CN-102159554-A | Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2011-08-17 | — | — | CN | disclosed |
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2011-05-12 | — | — | US | disclosed |
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2011-05-12 | — | — | US | disclosed |
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112107-A1 | SUBSTITUTED 6-(1-PIPERAZINYL)-PYRIDAZINES AS 5-HT6 RECEPTOR ANTAGONISTS | HTR6, HTR5A, HTR1A | BPTF 2547/4885HTR6 1/4885MAOB 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.